# Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile

> **NCT01226407** · PHASE1 · UNKNOWN · sponsor: **CrystalGenomics, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Solid Tumour

## Interventions

- **DRUG:** CG200745

## Key facts

- **NCT ID:** NCT01226407
- **Lead sponsor:** CrystalGenomics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-09
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2012-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01226407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01226407, "Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01226407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*